Bank of New York Mellon’s Infinity Pharmaceuticals, Inc. INFI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-34,188
| Closed | -$7.2K | – | 4437 |
|
|
2023
Q2 | $7.2K | Sell |
34,188
-22,616
| -40% | -$3.93K | ﹤0.01% | 4356 |
|
|
2023
Q1 | $9.09K | Hold |
56,804
| – | – | ﹤0.01% | 4363 |
|
|
2022
Q4 | $31.5K | Sell |
56,804
-1,895
| -3% | -$1.61K | ﹤0.01% | 4300 |
|
|
2022
Q3 | $70K | Hold |
58,699
| – | – | ﹤0.01% | 4268 |
|
|
2022
Q2 | $37K | Sell |
58,699
-205,780
| -78% | -$158K | ﹤0.01% | 4414 |
|
|
2022
Q1 | $301K | Sell |
264,479
-930
| -0.4% | -$1.11K | ﹤0.01% | 4018 |
|
|
2021
Q4 | $597K | Buy |
265,409
+4,052
| +2% | +$10.2K | ﹤0.01% | 3685 |
|
|
2021
Q3 | $893K | Buy |
261,357
+23,622
| +10% | +$72.8K | ﹤0.01% | 3453 |
|
|
2021
Q2 | $711K | Buy |
237,735
+174,698
| +277% | +$553K | ﹤0.01% | 3599 |
|
|
2021
Q1 | $204K | Sell |
63,037
-6,467
| -9% | -$21.6K | ﹤0.01% | 4054 |
|
|
2020
Q4 | $147K | Hold |
69,504
| – | – | ﹤0.01% | 4030 |
|
|
2020
Q3 | $81K | Sell |
69,504
-1
| -0% | -$1 | ﹤0.01% | 3978 |
|
|
2020
Q2 | $63K | Hold |
69,505
| – | – | ﹤0.01% | 3956 |
|
|
2020
Q1 | $58K | Sell |
69,505
-413
| -0.6% | -$479 | ﹤0.01% | 3952 |
|
|
2019
Q4 | $67K | Hold |
69,918
| – | – | ﹤0.01% | 4068 |
|
|
2019
Q3 | $72K | Hold |
69,918
| – | – | ﹤0.01% | 4071 |
|
|
2019
Q2 | $126K | Hold |
69,918
| – | – | ﹤0.01% | 3998 |
|
|
2019
Q1 | $131K | Sell |
69,918
-2,338
| -3% | -$3.42K | ﹤0.01% | 3963 |
|
|
2018
Q4 | $85K | Buy |
72,256
+30,622
| +74% | +$55.1K | ﹤0.01% | 3986 |
|
|
2018
Q3 | $113K | Hold |
41,634
| – | – | ﹤0.01% | 4022 |
|
|
2018
Q2 | $80K | Sell |
41,634
-7,883
| -16% | -$15.9K | ﹤0.01% | 4032 |
|
|
2018
Q1 | $104K | Buy |
49,517
+7,883
| +19% | +$16.9K | ﹤0.01% | 4053 |
|
|
2017
Q4 | $85K | Sell |
41,634
-4,351
| -9% | -$9.03K | ﹤0.01% | 4128 |
|
|
2017
Q3 | $61K | Buy |
45,985
+718
| +2% | +$892 | ﹤0.01% | 4076 |
|
|
2017
Q2 | $70K | Sell |
45,267
-125,382
| -73% | -$242K | ﹤0.01% | 4089 |
|
|
2017
Q1 | $551K | Buy |
170,649
+443
| +0.3% | +$1.09K | ﹤0.01% | 3515 |
|
|
2016
Q4 | $230K | Sell |
170,206
-42,933
| -20% | -$56.1K | ﹤0.01% | 3856 |
|
|
2016
Q3 | $332K | Sell |
213,139
-40,880
| -16% | -$62.8K | ﹤0.01% | 3723 |
|
|
2016
Q2 | $336K | Buy |
254,019
+9,876
| +4% | +$46.2K | ﹤0.01% | 3703 |
|
|
2016
Q1 | $1.29M | Buy |
244,143
+26,569
| +12% | +$163K | ﹤0.01% | 2915 |
|
|
2015
Q4 | $1.71M | Sell |
217,574
-20,206
| -8% | -$174K | ﹤0.01% | 2817 |
|
|
2015
Q3 | $2.01M | Sell |
237,780
-51,180
| -18% | -$472K | ﹤0.01% | 2738 |
|
|
2015
Q2 | $3.16M | Sell |
288,960
-13,614
| -4% | -$175K | ﹤0.01% | 2634 |
|
|
2015
Q1 | $4.23M | Buy |
302,574
+6,723
| +2% | +$103K | ﹤0.01% | 2401 |
|
|
2014
Q4 | $5M | Sell |
295,851
-7,055
| -2% | -$103K | ﹤0.01% | 2315 |
|
|
2014
Q3 | $4.07M | Buy |
302,906
+42,005
| +16% | +$500K | ﹤0.01% | 2436 |
|
|
2014
Q2 | $3.32M | Sell |
260,901
-39,938
| -13% | -$416K | ﹤0.01% | 2597 |
|
|
2014
Q1 | $3.58M | Buy |
300,839
+47,384
| +19% | +$636K | ﹤0.01% | 2505 |
|
|
2013
Q4 | $3.5M | Buy |
253,455
+3,873
| +2% | +$54.7K | ﹤0.01% | 2520 |
|
|
2013
Q3 | $4.35M | Buy |
249,582
+28,368
| +13% | +$543K | ﹤0.01% | 2326 |
|
|
2013
Q2 | $3.58M | Buy |
+221,214
| New | +$6.85M | ﹤0.01% | 2392 |
|
Other funds holding INFI
Bank of New York Mellon's INFI Position: Q3 2023 in Review
Bank of New York Mellon sold out of Infinity Pharmaceuticals, Inc. (INFI) in Q3 2023, closing a stake of 34,188 shares — an estimated $7.2K sold.
Bank of New York Mellon first reported a position in INFI in Q2 2013 and held it in 41 quarters. The position peaked at $5M in Q4 2014. 3 funds tracked by Wall St. Rank hold INFI as of Q3 2023.
- Bank of New York Mellon reported no remaining Infinity Pharmaceuticals, Inc. position as of Q3 2023 after selling out during the quarter.
- Bank of New York Mellon sold 34,188 Infinity Pharmaceuticals, Inc. shares in Q3 2023, an estimated $7.2K.
- Bank of New York Mellon first reported a position in Infinity Pharmaceuticals, Inc. in Q2 2013 and held it in 41 quarters.
- Bank of New York Mellon's Infinity Pharmaceuticals, Inc. position peaked at $5M in Q4 2014.
- 3 funds tracked by Wall St. Rank held Infinity Pharmaceuticals, Inc. as of Q3 2023.
Based on Bank of New York Mellon's 13F filing for Q3 2023, filed 24 Oct 2023.